{"id":755,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"bremelanotide-reconnect-phase-3-trials-and-fda-label","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","title":{"rendered":"\u062a\u062c\u0627\u0631\u0628 Bremelanotide RECONNECT: \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0646\u0637\u0627\u0642 FDA"},"content":{"rendered":"

\u064a\u062a\u0645\u062a\u0639 Bremelanotide \u0628\u0633\u062c\u0644 \u062d\u0642\u064a\u0642\u064a \u0644\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0644\u0643\u0646 \u0646\u0637\u0627\u0642\u0647 \u0636\u064a\u0642. \u062f\u0631\u0633\u062a \u062a\u062c\u0627\u0631\u0628 RECONNECT \u0627\u0644\u0646\u0633\u0627\u0621 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0645\u0627 \u0642\u0628\u0644 \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b \u0645\u0639 HSDD \u0627\u0644\u0645\u0643\u062a\u0633\u0628\u0629 \u0648\u0627\u0644\u0645\u0639\u0645\u0645\u0629 - \u0648\u0644\u064a\u0633 \u0627\u0644\u0631\u062c\u0627\u0644\u060c \u0623\u0648 \u062a\u062d\u0633\u064a\u0646 \u0627\u0644\u0623\u062f\u0627\u0621 \u0623\u0648 \u0645\u0627\u062f\u0629 \u0628\u062d\u062b\u064a\u0629 \u0639\u0627\u0645\u0629 PT-141.<\/p>

\u0627\u0644\u0623\u062f\u0644\u0629 \u0641\u064a \u0644\u0645\u062d\u0629<\/h2>
  • \u062a\u062c\u0627\u0631\u0628 3 \u0639\u0644\u0649 \u0645\u0631\u062d\u0644\u062a\u064a\u0646 \u062a\u0645 \u0627\u062e\u062a\u064a\u0627\u0631\u0647\u0627 \u0628\u0634\u0643\u0644 \u0639\u0634\u0648\u0627\u0626\u064a \u0644\u0644\u0646\u0633\u0627\u0621 1,267\u061b \u0648\u0643\u0627\u0646 1,202 \u0641\u064a \u0645\u062c\u062a\u0645\u0639 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629.<\/li>
  • \u0641\u0636\u0644\u062a \u0627\u0644\u062a\u063a\u064a\u064a\u0631\u0627\u062a \u0628\u064a\u0646 \u0627\u0644\u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u0628\u0631\u064a\u0645\u064a\u0644\u0627\u0646\u0648\u062a\u064a\u062f \u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u0646\u0642\u0627\u0637 \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0631\u063a\u0628\u0629 \u0648\u0627\u0644\u0636\u064a\u0642\u060c \u0644\u0643\u0646 \u0645\u0642\u064a\u0627\u0633 \u0627\u0644\u062d\u062f\u062b \u0627\u0644\u0645\u064f\u0631\u0636\u064a \u0628\u0639\u062f \u0627\u0644\u062d\u062f\u062b \u0644\u0645 \u064a\u062e\u062a\u0644\u0641 \u0628\u0634\u0643\u0644 \u0643\u0628\u064a\u0631.<\/li>
  • \u062d\u062f\u062b \u0627\u0644\u063a\u062b\u064a\u0627\u0646 \u0648\u0627\u0644\u0627\u062d\u0645\u0631\u0627\u0631 \u0648\u0627\u0644\u0635\u062f\u0627\u0639 \u0641\u064a 10% \u0639\u0644\u0649 \u0627\u0644\u0623\u0642\u0644 \u0648\u0643\u0627\u0646\u0648\u0627 \u0623\u0643\u062b\u0631 \u0634\u064a\u0648\u0639\u064b\u0627 \u0645\u0646 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0648\u0647\u0645\u064a.<\/li><\/ul><\/div><\/div>
    \"\u062a\u0635\u0648\u0631
    \u0627\u0644\u0631\u0633\u0645 \u0627\u0644\u062a\u0648\u0636\u064a\u062d\u064a \u0644\u0644\u0628\u062d\u062b \u0627\u0644\u062a\u062d\u0631\u064a\u0631\u064a \u0627\u0644\u0623\u0635\u0644\u064a. \u0625\u0646\u0647\u0627 \u0644\u064a\u0633\u062a \u0631\u0642\u0645 \u062f\u0631\u0627\u0633\u0629\u060c \u0623\u0648 \u0635\u0648\u0631\u0629 \u0645\u0631\u064a\u0636\u060c \u0623\u0648 \u0635\u0648\u0631\u0629 \u0644\u0644\u0645\u0646\u062a\u062c\u060c \u0623\u0648 \u0646\u062a\u064a\u062c\u0629 \u0641\u062d\u0635 \u0645\u0642\u062f\u0645\u0629 \u0623\u0648 \u062a\u0645\u062b\u064a\u0644 \u0644\u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c.<\/figcaption><\/figure>

    \u0633\u062c\u0644 \u0627\u0644\u062f\u0631\u0627\u0633\u0629<\/h2>

    \u0643\u0627\u0646\u062a \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0627\u0644\u0645\u0634\u062a\u0631\u0643\u0629 \u0647\u064a \u0627\u0644\u062a\u063a\u064a\u064a\u0631 \u0641\u064a \u062f\u0631\u062c\u0629 \u0645\u062c\u0627\u0644 \u0627\u0644\u0631\u063a\u0628\u0629 FSFI \u0648\u0639\u0646\u0635\u0631 \u0627\u0644\u0627\u0633\u062a\u063a\u0627\u062b\u0629 \u0645\u0646 FSDS-DAO. \u0643\u0627\u0646\u062a \u0627\u062e\u062a\u0644\u0627\u0641\u0627\u062a \u0627\u0644\u0631\u063a\u0628\u0629 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u062f\u0631\u0627\u0633\u0629 \u0647\u064a 0.30 \u06480.42\u061b \u0643\u0627\u0646\u062a \u0627\u062e\u062a\u0644\u0627\u0641\u0627\u062a \u0627\u0644\u0627\u0633\u062a\u063a\u0627\u062b\u0629 \u22120.37 \u0648 \u22120.29. \u0644\u0627 \u062a\u0635\u0641 \u0627\u0644\u0623\u0647\u0645\u064a\u0629 \u0627\u0644\u0625\u062d\u0635\u0627\u0626\u064a\u0629 \u0641\u064a \u062d\u062f \u0630\u0627\u062a\u0647\u0627 \u062d\u062c\u0645 \u0623\u0648 \u0623\u0647\u0645\u064a\u0629 \u0627\u0644\u0645\u0646\u0641\u0639\u0629 \u0644\u0643\u0644 \u0641\u0631\u062f.<\/p>

    \u062a\u0635\u0645\u064a\u0645<\/strong>\u062a\u062c\u0631\u0628\u062a\u0627\u0646 \u0645\u062a\u0645\u0627\u062b\u0644\u062a\u0627\u0646 \u0639\u0634\u0648\u0627\u0626\u064a\u062a\u0627\u0646\u060c \u0645\u0632\u062f\u0648\u062c\u062a\u0627 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0645\u062a\u062d\u0643\u0645\u062a\u0627\u0646 \u0628\u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0648\u0647\u0645\u064a 3<\/span><\/div>
    \u0639\u0634\u0648\u0627\u0626\u064a\u0629<\/strong>1,267 \u0627\u0644\u0646\u0633\u0627\u0621 \u0642\u0628\u0644 \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b<\/span><\/div>
    \u0641\u0631\u0642 \u0627\u0644\u0631\u063a\u0628\u0629 \u0627\u0644\u0645\u062a\u0643\u0627\u0645\u0644\u0629<\/strong>0.35 \u0645\u0642\u0627\u0628\u0644 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a\u061b \u0641<0.001<\/span><\/div>
    \u0641\u0631\u0642 \u0627\u0644\u0634\u062f\u0629 \u0627\u0644\u0645\u062a\u0643\u0627\u0645\u0644<\/strong>\u22120.33 \u0645\u0642\u0627\u0628\u0644 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0648\u0647\u0645\u064a\u061b \u0641<0.001<\/span><\/div>
    \u062d\u062f\u0648\u062f \u0627\u0644\u062a\u0633\u0645\u064a\u0629<\/strong>\u0644\u0627 \u064a\u064f\u0634\u0627\u0631 \u0625\u0644\u064a\u0647 \u0644\u0644\u0646\u0633\u0627\u0621 \u0648\u0627\u0644\u0631\u062c\u0627\u0644 \u0648\u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0628\u0639\u062f \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b \u0623\u0648 \u0644\u062a\u062d\u0633\u064a\u0646 \u0627\u0644\u0623\u062f\u0627\u0621<\/span><\/div><\/div><\/div>

    \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0641\u064a \u0627\u0644\u0633\u064a\u0627\u0642<\/h2>

    \u062a\u0634\u064a\u0631 \u0627\u0644\u0648\u0631\u0642\u0629 \u0625\u0644\u0649 \u0639\u062f\u0645 \u0648\u062c\u0648\u062f \u0627\u062e\u062a\u0644\u0627\u0641 \u0643\u0628\u064a\u0631 \u0641\u064a \u0627\u0644\u0645\u062c\u0645\u0648\u0639\u0629 \u0641\u064a \u0627\u0644\u0646\u0633\u0628\u0629 \u0627\u0644\u0645\u0626\u0648\u064a\u0629 \u0644\u0644\u0623\u062d\u062f\u0627\u062b \u0627\u0644\u062c\u0646\u0633\u064a\u0629 \u0627\u0644\u0645\u0631\u0636\u064a\u0629 \u0641\u064a \u0627\u0644\u062a\u062d\u0644\u064a\u0644 \u0627\u0644\u0644\u0627\u062d\u0642. \u064a\u0624\u062f\u064a \u0627\u0644\u062d\u0641\u0627\u0638 \u0639\u0644\u0649 \u0647\u0630\u0647 \u0627\u0644\u0646\u062a\u064a\u062c\u0629 \u0627\u0644\u062e\u0627\u0644\u064a\u0629 \u0625\u0644\u0649 \u0625\u0628\u0642\u0627\u0621 \u0627\u0644\u0633\u062c\u0644 \u0623\u0643\u062b\u0631 \u0625\u0641\u0627\u062f\u0629 \u0645\u0646 \u0645\u0644\u062e\u0635 \u0627\u0644\u0641\u0648\u0627\u0626\u062f \u0641\u0642\u0637.<\/p>

    \u062a\u062d\u062f\u062f \u0639\u0644\u0627\u0645\u0629 DailyMed \u0627\u0644\u062d\u0627\u0644\u064a\u0629 Vyleesi \u0639\u0644\u0649 \u0623\u0646\u0647 \u062d\u0642\u0646 \u0628\u0631\u064a\u0645\u064a\u0644\u0627\u0646\u0648\u062a\u064a\u062f \u062a\u062d\u062a NDA 210557 \u0648\u062a\u062f\u0631\u062c \u0632\u064a\u0627\u062f\u0629 \u0639\u0627\u0628\u0631\u0629 \u0641\u064a \u0636\u063a\u0637 \u0627\u0644\u062f\u0645\u060c \u0648\u0627\u0646\u062e\u0641\u0627\u0636 \u0645\u0639\u062f\u0644 \u0636\u0631\u0628\u0627\u062a \u0627\u0644\u0642\u0644\u0628\u060c \u0648\u0627\u0644\u063a\u062b\u064a\u0627\u0646\u060c \u0648\u0641\u0631\u0637 \u0627\u0644\u062a\u0635\u0628\u063a \u0627\u0644\u0628\u0624\u0631\u064a \u0628\u064a\u0646 \u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0627\u0644\u0645\u0647\u0645\u0629. \u062a\u0646\u062a\u0645\u064a \u0647\u0630\u0647 \u0627\u0644\u062a\u0633\u0645\u064a\u0629 \u0625\u0644\u0649 \u0627\u0644\u0635\u064a\u063a\u0629 \u0627\u0644\u0645\u0639\u062a\u0645\u062f\u0629\u060c \u0648\u0644\u064a\u0633 \u0625\u0644\u0649 \u0639\u0646\u0635\u0631 \u0641\u064a \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0628\u062d\u062b.<\/p>

    \u0645\u0627 \u0644\u0627 \u062a\u0633\u062a\u0637\u064a\u0639 \u0627\u0644\u0623\u062f\u0644\u0629 \u0625\u062b\u0628\u0627\u062a\u0647<\/h2>

    \u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u0623\u062f\u0644\u0629 \u0648\u0627\u0644\u062f\u0644\u0627\u0644\u0629 \u0645\u062d\u062f\u062f\u0629\u061b \u0627\u062f\u0639\u0627\u0621\u0627\u062a \u0627\u0644\u0623\u062f\u0627\u0621 \u0627\u0644\u062c\u0646\u0633\u064a \u0627\u0644\u0623\u0648\u0633\u0639 \u063a\u064a\u0631 \u0645\u062f\u0639\u0648\u0645\u0629.<\/p>

    \u0648\u0643\u0627\u0646\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0645\u062d\u0648\u0631\u064a\u0629 \u0645\u0645\u0648\u0644\u0629 \u0645\u0646 \u0627\u0644\u0635\u0646\u0627\u0639\u0629.<\/p>

    \u0627\u0644\u062c\u0632\u0621 \u0627\u0644\u0646\u0634\u0637 \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0644\u0627 \u064a\u062c\u0639\u0644 \u0627\u0644\u0645\u0627\u062f\u0629 \u0645\u0646 \u0645\u0635\u0627\u062f\u0631 \u0645\u0633\u062a\u0642\u0644\u0629 \u062f\u0648\u0627\u0621 \u0645\u0639\u062a\u0645\u062f.<\/p>","protected":false},"excerpt":{"rendered":"

    \u064a\u062a\u0645\u062a\u0639 Bremelanotide \u0628\u0633\u062c\u0644 \u062d\u0642\u064a\u0642\u064a \u0644\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0644\u0643\u0646 \u0646\u0637\u0627\u0642\u0647 \u0636\u064a\u0642. \u062f\u0631\u0633\u062a \u062a\u062c\u0627\u0631\u0628 RECONNECT \u0627\u0644\u0646\u0633\u0627\u0621 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0645\u0627 \u0642\u0628\u0644 \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b \u0645\u0639 HSDD \u0627\u0644\u0645\u0643\u062a\u0633\u0628\u0629 \u0648\u0627\u0644\u0645\u0639\u0645\u0645\u0629 - \u0648\u0644\u064a\u0633 \u0627\u0644\u0631\u062c\u0627\u0644\u060c \u0623\u0648 \u062a\u062d\u0633\u064a\u0646 \u0627\u0644\u0623\u062f\u0627\u0621 \u0623\u0648 \u0645\u0627\u062f\u0629 \u0628\u062d\u062b\u064a\u0629 \u0639\u0627\u0645\u0629 PT-141.<\/p>","protected":false},"author":1,"featured_media":739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Published evidence review","pim_evidence_level":"Two randomized phase 3 trials plus current FDA-approved prescribing information","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nBremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope<\/title>\n<meta name=\"description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\" \/>\n<meta property=\"og:description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/ar\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u062a\u062c\u0627\u0631\u0628 Bremelanotide RECONNECT: \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0646\u0637\u0627\u0642 FDA","description":"\u064a\u062a\u0645\u062a\u0639 Bremelanotide \u0628\u0633\u062c\u0644 \u062d\u0642\u064a\u0642\u064a \u0644\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0644\u0643\u0646 \u0646\u0637\u0627\u0642\u0647 \u0636\u064a\u0642. \u062f\u0631\u0633\u062a \u062a\u062c\u0627\u0631\u0628 RECONNECT \u0627\u0644\u0646\u0633\u0627\u0621 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0645\u0627 \u0642\u0628\u0644 \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b \u0645\u0639\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_locale":"ar_AR","og_type":"article","og_title":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","og_description":"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026","og_url":"https:\/\/nhdbio.com\/ar\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"NHD Technical Team","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u0629 \u0648\u0627\u062d\u062f\u0629"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","url":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","name":"\u062a\u062c\u0627\u0631\u0628 Bremelanotide RECONNECT: \u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0648\u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0648\u0646\u0637\u0627\u0642 FDA","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"\u064a\u062a\u0645\u062a\u0639 Bremelanotide \u0628\u0633\u062c\u0644 \u062d\u0642\u064a\u0642\u064a \u0644\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0645\u0646 FDA\u060c \u0644\u0643\u0646 \u0646\u0637\u0627\u0642\u0647 \u0636\u064a\u0642. \u062f\u0631\u0633\u062a \u062a\u062c\u0627\u0631\u0628 RECONNECT \u0627\u0644\u0646\u0633\u0627\u0621 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0645\u0627 \u0642\u0628\u0644 \u0627\u0646\u0642\u0637\u0627\u0639 \u0627\u0644\u0637\u0645\u062b \u0645\u0639\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u0627\u0644\u0641\u0631\u064a\u0642 \u0627\u0644\u0641\u0646\u064a NHD","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"\u064a\u062d\u062a\u0641\u0638 \u0641\u0631\u064a\u0642 NHD \u0627\u0644\u0641\u0646\u064a \u0628\u0648\u062b\u0627\u0626\u0642 \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a \u0648\u0645\u0644\u062e\u0635\u0627\u062a \u0627\u0644\u0623\u062f\u0644\u0629. \u062a\u0631\u062a\u0628\u0637 \u0627\u0644\u0645\u0642\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0628\u0627\u0644\u0623\u0648\u0631\u0627\u0642 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0645\u0646 \u0642\u0628\u0644 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u060c \u0648\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0648\u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629\u060c \u0648\u062a\u062d\u062a\u0641\u0638 \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0641\u0627\u0631\u063a\u0629 \u0648\u0642\u064a\u0648\u062f \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u062a\u0645\u064a\u0632 \u0627\u0644\u062a\u062f\u062e\u0644\u0627\u062a \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629 \u0639\u0646 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0628\u0645\u0633\u0627\u0639\u062f\u0629 AI \u0644\u0644\u0647\u064a\u0643\u0644\u061b \u062a\u0638\u0644 \u0631\u0648\u0627\u0628\u0637 \u0627\u0644\u0645\u0635\u062f\u0631 \u0648\u062d\u062f\u0648\u062f \u0627\u0644\u0623\u062f\u0644\u0629 \u0645\u0631\u0626\u064a\u0629. \u0647\u0630\u0627 \u0627\u0644\u0639\u0645\u0644 \u0644\u064a\u0633 \u0645\u0631\u0627\u062c\u0639\u0629 \u0623\u0642\u0631\u0627\u0646 \u0645\u0633\u062a\u0642\u0644\u0629 \u0623\u0648 \u0646\u0635\u064a\u062d\u0629 \u0637\u0628\u064a\u0629.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/ar\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/comments?post=755"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/categories?post=755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/tags?post=755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}